Key Drivers
- Strong Liquidity
- Rising Leverage
- Severe Cash Burn
AIAI Summary
BEAM is now a concentrated, catalyst-driven biotech bet: sustained BEAM-302 durability and an accelerated-approval path could unlock outsized value, while risto-cel's prospective 2026/27 BLA adds a second commercialization lever; investors should prioritize pivotal data, FDA execution, and cash burn over platform narrative.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Leverage
- •Severe Cash Burn
BEAM's strong liquidity is outweighed by severe losses, accelerating cash burn, declining equity, and a valuation that remains demanding relative to weak revenue.
Price Behavior
Key Price Behavior Insights:
- •Monthly downtrend
- •Oversold rebound
- •Support test
BEAM remains bearish over the last month, but an oversold bounce may hold if $23.10–$23.22 support withstands selling; watch $26.83 resistance for confirmation.
Two-session rebound from recent lows amid oversold momentum
Sentiment & News
Key News Insights:
- •Durable BEAM-302 data
- •Commercial leadership added
- •Investor legal probes
Beam's advancing BEAM-302 data and commercialization hiring support upside potential, though investor investigations and share volatility remain key risks.
Positive clinical momentum may support BEAM shares, but legal headlines and elevated trading volatility could pressure sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings